<DOC>
	<DOCNO>NCT00090038</DOCNO>
	<brief_summary>The purpose study provide treatment patient relapse Non-Hodgkin 's lymphoma ( NHL ) refractory NHL , test immunity study subject receive four treatment rituximab .</brief_summary>
	<brief_title>Effect Rituximab Immunological Recall Response Specific Antigens Treatment Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Signed IRBapproved informed consent . Age &gt; /=40 year . Men woman reproductive potential following accept birth control method . Histologic confirmation lowgrade follicular , Bcell NHL prior study entry . Relapsed ( maximum 5 relapse ) refractory , lowgrade follicular , CD20+ , Bcell NHL . WHO performance status &lt; /= 2 . Expected survival &gt; /= 1 year . Acceptable hematologic status , liver function , renal function , pulmonary function . Patients must recover nonhematological toxicity associate prior surgery , radiation treatment , chemotherapy , biological therapy , bone marrow transplant , investigational drug , immunotherapy . Known history tetanus toxoid immunization positive tetanus titer screen visit . Active autoimmune disease . Exposure rituximab within 12 month prior Day 1 . Chemotherapy within 3 month prior Day 1 . Previous immunization tetanus toxoid within 2 year prior Day 1 . Previous exposure KLH . Receipt intravenous intramuscular immunoglobulin ( IVIG IMIG ) within 30 day Day 1 . Known history hepatitis hepatic disease , HIV infection , AIDS . Current use ( include `` recreational use '' ) illicit drug history drug alcohol abuse within 5 year prior Day 1 . Prior diagnosis aggressive NHL mantlecell lymphoma . Chronic lymphocytic leukemia ( CLL ) . Small lymphocytic lymphoma ( IWF A ) peripheral blood lymphocyte count &gt; 5,000 cells/mm3 . History primary malignancy , exception squamous cell carcinoma basal cell carcinoma skin , situ carcinoma cervix , treated prostate cancer subject disease free least 3 year . Serious nonmalignant disease ( e.g. , congestive heart failure , hydronephrosis ) ; active , uncontrolled bacterial , viral , fungal infection ; condition would compromise protocol objective opinion investigator and/or sponsor . Known allergy contraindication tetanus toxoid KLH . Known allergy shellfish . Presence proteinlosing enteropathy . Major surgery , diagnostic surgery , within 4 week prior Day 1 . Participation another clinical study investigational agent device within last year . The subject participate clinical study investigational agent device course study . Pregnant lactate female subject</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>